65.5 F
San Diego
Monday, Mar 18, 2024
-Advertisement-

Navy Turns Vical Loose on H1N1 Vaccine

San Diego-based vaccine developer Vical is partnering with the U.S. Naval Medical Research Center to expedite a potential defense against the H1N1 flu virus, it said May 6.

Under a cooperative research and development agreement, Vical and the U.S. Navy biomedical research organization will work toward a common goal of bringing its early-stage Phase 1 DNA vaccine into clinical testing “as quickly as possible.”

In late April, Vical told the Business Journal that its technology could make a swine flu vaccine available in six to nine weeks after receiving the necessary genetic code of the virus.

Vical would be responsible for securing regulatory approval of the vaccine for use in the United States and other countries.

“We believe our technology is particularly well-suited to emerging infectious diseases like H1N1 influenza for which conventional vaccine technologies are too slow in both development and manufacturing,” said Vical CEO Vijay Samant in a release.

, Heather Chambers

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-